Can you discuss the potential impact of emerging therapies, such as gene editing or targeted immunotherapies, on hematology practice?
- 1 Answers
- 364 Views
- I also Faced
- E-Mail Answers
Answer Posted / Rajat Prakash Singh
Emerging therapies like gene editing (CRISPR) and targeted immunotherapies are revolutionizing hematology practice. Gene editing holds promise for treating genetic disorders like sickle cell disease and beta-thalassemia by correcting the mutated genes responsible for these conditions. Targeted immunotherapies, on the other hand, can help in managing cancerous blood cells, such as chronic myeloid leukemia (CML). These advancements could lead to improved patient outcomes, reduced side effects, and personalized medicine. However, they also present challenges related to cost, accessibility, and ethical considerations.
| Is This Answer Correct ? | 0 Yes | 0 No |
Post New Answer View All Answers
No New Questions to Answer in this Category !! You can
Post New Questions
Answer Questions in Different Category
